NEW YORK (GenomeWeb) – Software firm Syapse said today that it raised $10 million in a Series B financing round led by Safeguard Scientifics with participation from Series A investor The Social+Capital Partnership.
Syapse said that it will use the funds to expand its sales, marketing, and client services, as well as further accelerate product development. The funds will also support the firm's efforts to provide its Precision Medicine Data platform to healthcare providers, enabling them to use genomics and clinical data in their treatment decisions.
"At Syapse, we are focused on improving healthcare though software that helps clinicians utilize complex genomic and clinical data," Glenn Winokur, Syapse cofounder and CEO, said in a statement, adding that "software that helps clinicians make sense of complex data at scale is critical to enabling precision medicine."
The company's platform has tools to integrate genomic and clinical data with care pathways and medical knowledge bases, providing clinicians with actionable insights to enable diagnosis and treatment. The system supports longitudinal tracking of patients over time and integrates data from electronic medical records, molecular testing labs, imaging and billing systems.
The Palo Alto, Calif.-based firm noted that it has raised a total of $14.5 million to date.